Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: Flexibility may help

Haematologica

Volumn 95, Issue 4, 2010, Pages 529-534

  Falini, Brunangelo ^a   Martelli, Maria Paola ^a   Pileri, Stefano A ^b   Mecucci, Cristina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOPHOSMIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CLASSIFICATION; CANCER SURVIVAL; CYTOPLASM; EDITORIAL; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; WESTERN BLOTTING;

HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS;

EID: 77950685484     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.017822     Document Type: Editorial

References (45)

1. Lowenberg B. Acute myeloid leukemia: the challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008;1-11.
2. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254-66.
3. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899-902.
4. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): bio- logic and clinical features. Blood. 2007;109(3):874-85.
5. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophos- min. Proc Natl Acad Sci USA. 2008;105(10):3945-50.
6. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-18.
7. Arber D, Brunning RD, Le Beau MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH et al., Eds, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC), Lyon, 2008, p.110-23.
8. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a cancer and leukemia group B study. J Clin Oncol. 2010;28(4):596-604.
9. Roti G, Rosati R, Bonasso R, Gorello P, Diverio D, Martelli MF, et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn. 2006;8(2):254-9.
10. Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, et al. Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. J Mol Diagn. 2008;10(4): 338-45.
11. Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, et al. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. J Mol Diagn. 2008;10(3):212-6.
12. Szankasi P, Jama M, Bahler DW. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn. 2008;10(3):236-41.
13. Wertheim G, Bagg A. Nucleophosmin (NPM1) mutations in acute myeloid leukemia: an ongoing (cytoplasmic) tale of dueling muta- tions and duality of molecular genetic testing methodologies. J Mol Diagn. 2008;10(3):198-202.
14. Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol. 2008;142(3):489-92.
15. Dvorakova D, Lengerova M, Pospisilova J, Palasek I, Mayer J. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations. Leukemia. 2009;23(4):793-6.
16. Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, et al. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark. 2009;5(1):51-8.
17. Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C, et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecu- lar status of a significant fraction of myeloid sarcomas. Leukemia. 2007;21(7):1566-70.
18. Rau R, Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol. 2009;27(4):171-81.
19. Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF, et al. Identification and functional characterization of a cytoplasmic nucle- ophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. 2007;21(5):1099-103.
20. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106(4):1419-22.
21. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007;110(3):979-85.
22. Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplica- tion in NPM1-exon 12. Leukemia. 2007;21(2):366-7.
23. Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008;93(5):775-9.
24. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103-8.
25. Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bear- ing nucleophosmin (NPM1) mutations. Leukemia. 2007;21(5):998-1004.
26. Barragan E, Pajuelo JC, Ballester S, Fuster O, Cervera J, Moscardo F, et al. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression. Clin Chim Acta. 2008;395(1-2):120-3.
27. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kroger N. Quantitative monitoring of NPM1 mutations provides a valid mini- mal residual disease parameter following allogeneic stem cell trans- plantation. Exp Hematol. 2009;37(1):135-42.
28. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220-31.
29. Ommen HB, Schnittger S, Jovanovic JV, Ommen IB, Hasle H, Ostergaard M, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1 and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115(2):198-205.
30. Martelli MP, Manes N, Liso A, Pettirossi V, Verducci Galletti B, Bigerna B, et al. A western blot assay for detecting mutant nucle- ophosmin (NPM1) proteins in acute myeloid leukaemia. Leukemia. 2008;22(12):2285-8.
31. Arber DA. Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol. 2001;115(4):552-60.
32. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
33. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-9.
34. Schoch C, Schnittger S, Kern W, Dugas M, Hiddemann W, Haferlach T. Acute myeloid leukemia with recurring chromosome abnormali- ties as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica. 2003;88(3):351-2.
35. Tiacci E, Pileri S, Orleth A, Pacini R, Tabarrini A, Frenguelli F, et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res. 2004;64(20):7399-404.
36. Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, et al. Detection of acute leukemia cells with mixed lin- eage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia. 2000;14(7):1232-8.
37. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108(6):1999-2005.
38. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23(10):1731-43.
39. Luo J, Qi C, Xu W, Kamel-Reid S, Brandwein J, Chang H. Cytoplasmic expression of nucleophosmin accurately predicts muta- tion in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype. Am J Clin Pathol. 2010;133(1):34-40.
40. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, et al. Cytoplasmic localization of nucleophosmin in bone mar- row blasts of acute myeloid leukemia patients is not completely con- cordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009;115(20):4737-44.
41. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood. 1997;90(10):4046-53.
42. Rego EM, Kim HT, Ruiz-Arguelles GJ, Uriarte R, Jacomo RH, Gutierrez-Aguirre H, et al. Improving the treatment outcome of acute promyelocytic leukemia in developing countries through International Cooperative Network. Report on the International Consortium on Acute Promyelocytic Leukemia Study Group. Blood. (ASH Annual Meeting Abstracts) 2009;114, 6.
43. Mattsson G, Turner SH, Cordell J, Ferguson DJ, Schuh A, Grimwade LF, et al. Can cytoplasmic nucleophosmin be detected by immunocy- tochemical staining of cell smears in acute myeloid leukemia? Haematologica. 2010;95(4):670-3.
44. Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, Tabarrini A, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood. 2006;108(13):4146-55.
45. Oelschlaegel U KS, Schaich M, Kroschinsky F, Parmentier S, Ehninger G, Thiede C. A rapid flow cytometric method for the detection of NPM1 mutated patients with acute myeloid leukemia (AML). Blood. (ASH Annual Meeting Abstracts) 2008;112:1490.